Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy

Eun, So Hee; Kim, Heung Dong; Eun, Baik Lin; Lee, In Kyu; Chung, Hee Jung; Kim, Joon Sik; Kang, Hoon Chul; Lee, Young Mock; Suh, Eun Sook; Kim, Dong Wook; Eom, Soyong; Lee, Joon Soo; Moon, Han Ku

doi:10.1016/j.seizure.2011.04.005

Cited by 35 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The proportion of patients achieving the primary outcome measure (seizure-free rate for 6 months) was comparable in both groups (63.1 % vs. 57.6 % respectively, p = 0.66) on intention-to-treat analysis [43]. There are no relevant trials for use of ZNS as adjunctive therapy in children with partial-onset seizures.…”

Section: Resultsmentioning

confidence: 99%

Pharmacotherapy of Focal Epilepsy in Children: A Systematic Review of Approved Agents

Arya

Glauser

2013

CNS Drugs

View full text Add to dashboard Cite

Background Partial-onset seizures contribute the bulk of seizure burden in childhood epilepsy. The therapeutic decision making involves consideration of factors specific to drug, patient and socioeconomic situation. Objectives This paper systematically reviews the available efficacy/effectiveness evidence for various anti-epileptic drugs (AED) as monotherapy and adjunctive therapy for partial-onset seizures in children. Data sources Relevant randomized clinical trials (RCTs) were identified by a structured PubMed search, supplemented by an additional hand search of reference lists and authors’ files. Study appraisal and synthesis methods Eligible studies were reviewed and data extracted into tables. Included RCTs were classified based on accepted published criteria. Outcomes Only efficacy and effectiveness outcome measures were evaluated since there is little scientifically rigorous comprehensive AED adverse effects data. Results Oxcarbazepine is the only AED with Class I evidence for efficacy/effectiveness as initial monotherapy for partial-onset seizures in children. Carbamazepine, clobazam, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, vigabatrin and zonisamide have, at best, Class III efficacy/effectiveness evidence for monotherapy of partialonset seizures in children. For adjunctive therapy, gabapentin, lamotrigine, levetiracetam, oxcarbazepine and topiramate have Class I efficacy/effectiveness evidence for treatment of pediatric partial-onset seizures. Conclusions and implications of key findings This efficacy/effectiveness analysis must not be used in isolation when selecting therapy. AED selection for a specific child needs to integrate a drug’s efficacy/effectiveness data with its safety and tolerability profile, pharmacokinetic properties, available formulations, and patient specific characteristics. It is critical that physicians and patients incorporate all these relevant variables when choosing AED therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Pharmacotherapy of Focal Epilepsy in Children: A Systematic Review of Approved Agents

Arya

Glauser

2013

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…[13][14][15][16][17][18] Two studies were excluded from the network due to different outcome measures 15 and the absence of a common comparator. [13][14][15][16][17][18] Two studies were excluded from the network due to different outcome measures 15 and the absence of a common comparator.…”

Section: Newly Diagnosed Focal Epilepsymentioning

confidence: 99%

Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta‐analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Zonisamide is chemically classified as a sulfonamide and is unrelated to other antiepileptic agents. Zonisamide is effective in the treatment partial seizures [11,24], childhood epilepsy [17], West syndrome (infantile spasms), and juvenile myoclonic epilepsy. General side effects of these three antiepileptic medications include nausea, vomiting, headache, mental status changes, neuropathy, and change in weight.…”

Section: Overview Of T-type Calcium Channel Blockersmentioning

confidence: 99%

T-type calcium channel blockers as neuroprotective agents

Kopecky

Liang

Bao

2014

Pflugers Arch - Eur J Physiol

View full text Add to dashboard Cite

T-type calcium channels are expressed in many diverse tissues, including neuronal, cardiovascular, and endocrine. T-type calcium channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. Calcium channel blockers have been developed to treat various diseases and their use clinically is widespread due to both their efficacy as well as their safety. Aside from their established clinical applications, recent studies have suggested neuroprotective effects of T-type calcium channels blockers. Many of the current T-type calcium channel blockers could act on other molecular targets besides T-type calcium channels making it uncertain whether their neuroprotective effects are solely due to blocking of T-type calcium channels. In this review, we discuss these drugs as well as newly developed chemical compounds that are designed to be more selective for T-type calcium channels. We review in vitro and in vivo evidence of neuroprotective effects by these T-type calcium channel blockers. We conclude by discussing possible molecular mechanisms underlying neuroprotective effects by T-type calcium channel blockers.

show abstract

Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy

Cited by 35 publications

References 17 publications

Pharmacotherapy of Focal Epilepsy in Children: A Systematic Review of Approved Agents

Pharmacotherapy of Focal Epilepsy in Children: A Systematic Review of Approved Agents

Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta‐analysis

T-type calcium channel blockers as neuroprotective agents

Contact Info

Product

Resources

About